Amarbir Bhullar, MD
Clinical Cardiac Electrophysiology · Ashland, KYNPI 1790199453
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (42.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Medtronic at 27.0% of the total. Reporting peaked in 2020 at $9,096 and has fallen 70.2% since, to $2,709 in 2025.
Across 319 payments — averaging $104.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$9K
- Boston Scientific$8K
- Biotronik Inc.$5K
- Abbott$4K
- Amgen$1K
- Philips North America LLC$1K
- plus $4K from 26 others
What the payments were for
- Grants$14,10842%
- Travel & lodging$8,11924%
- Food & beverage$10,43831%
- Education$7502%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 31 | $9,034 |
| Boston Scientific | 17 | $8,190 |
| Biotronik Inc. | 17 | $5,409 |
| Abbott | 43 | $4,379 |
| Amgen | 63 | $1,482 |
| Philips North America LLC | 11 | $1,236 |
| Biosense Webster, Inc. | 4 | $509 |
| Cardiva Medical, Inc. | 26 | $493 |
| Boehringer Ingelheim | 12 | $335 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $334 |
| Merck | 14 | $291 |
| Actelion Pharmaceuticals US, Inc. | 12 | $288 |
| Novartis | 10 | $192 |
| Lexicon Pharmaceuticals, Inc. | 4 | $188 |
| Bayer | 4 | $182 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $139 |
| Alnylam Pharmaceuticals Inc. | 6 | $139 |
| United Therapeutics Corporation | 3 | $116 |
| Pfizer | 5 | $86 |
| Chiesi USA, Inc. | 3 | $55 |
| Abiomed | 2 | $51 |
| Cordis US CORP. | 1 | $46 |
| GSK | 2 | $44 |
| AstraZeneca | 2 | $40 |
| Edwards Lifesciences | 1 | $33 |
| Cvrx, Inc. | 2 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Baylis Medical Company Inc | 1 | $14 |
| Convatec Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL BRADY$3,750
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$3,750
- ENSITE PRECISION$1,835
- BioMonitor$1,472
- Solia$1,236
- AMPLATZER AMULET$953
- AMVIA EDGE$923
- Selectra$923
- Acticor 7 VR-T DX$923
- Micra$597
- (9520) IGT Devices Undivided$518
- Repatha$372
- (9124) LM Undivided$318
- Rivacor$313
- Edora$313
- Acticor$313
- AMPLATZER$301
- QDOT MICRO Catheter$267
- Ensite Cardiac Mapping System$186
- COREVALVE EVOLUT R$155
How this compares
$33,414 in reported general payments places this provider in the 70th percentile of 57 clinical cardiac electrophysiology providers in Kentucky.
See all clinical cardiac electrophysiology providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $80,869 |
| XareltoRivaroxaban | 13 | $10,209 |
| Metoprolol Succinate | 70 | $1,113 |
| Flecainide Acetate | 28 | $628 |
| Carvedilol | 25 | $255 |
| Atorvastatin Calcium | 16 | $187 |
| Amiodarone Hcl | 12 | $160 |
| ClopidogrelClopidogrel Bisulfate | 15 | $118 |
| Metoprolol Tartrate | 19 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $86 | $80,86980 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 57 clinical cardiac electrophysiology providers in Kentucky.
Other clinical cardiac electrophysiology in Ashland
- Basel EdrisAshland$45K
- John VanderenAshland$19K
- Pratap SinghAshland$14K
- Aaron HesselsonAshland$9K
- Ola KhraishaAshland$4K
- Johan AasboLexington$451K
- Rajdeep GaitondeLouisville$404K
- Jeffrey StidamLouisville$196K
- Gery TomassoniLexington$196K
- Kent MorrisLouisville$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.